A versatile viral toolkit for functional discovery in the nervous system

Graphical abstract

Highlights

- Cell-type-specific targeting is required to study circuits and behaviors
- Factors such as transgene size limit the AAV payload available
- VTK is a set of optimized AAV backbones that overcomes these limitations

Authors

Gabrielle Pouchelon, Josselyn Vergara, Justin McMahon, ..., Gregg A. Wildenberg, Gordon Fishell, Jordane Dimidschstein

Correspondence

pouchel@cshl.edu (G.P.), jordane.dimidschstein@gmail.com (J.D.)

In brief

Pouchelon et al. develop an optimized and modular viral toolkit (VTK) that addresses key AAV limitations and allows for efficient combinatorial targeting of neuronal cell types. This approach allows efficient querying of neuronal biology using a wide array of genetically encoded tools.
A versatile viral toolkit for functional discovery in the nervous system

Gabrielle Pouchelon,1,2,7,8,* Josselyn Vergara,1,7 Justin McMahon,1,7 Bram L. Gorissen,1,2,7 Jessica D. Lin,1 Douglas Vormstein-Schneider,1 Jason L. Niehaus,3 Timothy J. Burbidge,1,2 Jason C. Wester,4 Mia Sherer,1,2 Marian Fernandez-Otero,1,2 Kathryn C. Allaway,1,2 Kenneth Pelkey,4 Ramesh Chittajallu,4 Chris J. McBain,4 Melina Fan,3 Jason S. Nasse,3 Gregg A. Wildenberg,5,6 Gordon Fishell,1,2 and Jordane Dimidschstein1,*

1Broad Institute, Stanley Center for Psychiatric Research, Cambridge, MA 02142, USA
2Harvard Medical School, Blavatnik Institute, Neurobiology, Boston, MA 02115, USA
3Addgene, Watertown, MA 02472, USA
4Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892, USA
5Department of Neurobiology, University of Chicago, Chicago, IL 60637, USA
6Biosciences Division, Argonne National Laboratory, Lemont, IL 60439, USA
7These authors contributed equally
8Lead contact
*Correspondence: pouchel@cshl.edu (G.P.), jordane.dimidschstein@gmail.com (J.D.)
https://doi.org/10.1016/j.crmeth.2022.100225

SUMMARY

The ability to precisely control transgene expression is essential for basic research and clinical applications. Adeno-associated viruses (AAVs) are non-pathogenic and can be used to drive stable expression in virtually any tissue, cell type, or species, but their limited genomic payload results in a trade-off between the transgenes that can be incorporated and the complexity of the regulatory elements controlling their expression. Resolving these competing imperatives in complex experiments inevitably results in compromises. Here, we assemble an optimized viral toolkit (VTK) that addresses these limitations and allows for efficient combinatorial targeting of cell types. Moreover, their modular design explicitly enables further refinements. We achieve this in compact vectors by integrating structural improvements of AAV vectors with innovative molecular tools. We illustrate the potential of this approach through a systematic demonstration of their utility for targeting cell types and querying their biology using a wide array of genetically encoded tools.

INTRODUCTION

Exploring biological systems requires the ability to selectively target particular cell types. Nowhere is this more evident than in the nervous system, where specialized cells function through the formation of canonical circuits (Tasic et al., 2018; Fishell and Kepecs, 2019). The use of transgenic animal models for targeted effector and sensor expression has transformed our understanding of the brain (Taniguchi et al., 2011; Madisen et al., 2015; He et al., 2016). However, flexibility in designing experiments that are reliant solely on transgenic animals remains costly, time consuming, and limiting. Given the current explosion in innovative molecular tools, recombinant adeno-associated viruses (AAVs) provide an ideal means for their rapid and efficient implementation (Blankvoort et al., 2018; Deverman et al., 2018; Dimidschstein et al., 2016; Jüttner et al., 2019; Vormstein-Schneider et al., 2020; Hrvatin et al., 2019; Graybuck et al., 2021; Michel et al., 2021; Lambert et al., 2021). Size limitations in AAVs demand careful consideration for attaining an optimal balance between payload and the regulatory elements controlling their expression (Bedbrook et al., 2018; Fenno et al., 2014, 2020). Over the past 10 years, a bewildering array of genetic components has been engineered into AAV backbones. This has resulted in the accumulation of elements included by historic happenstance rather than utility. Here, we create a viral toolkit (VTK) consisting of highly optimized AAV backbones that provides end users with the flexibility to implement complex targeting strategies.
RESULTS

Design of an optimized VTK for direct and combinatorial transgene expression

For efficient viral transgene expression, the payload of AAV vectors has to be limited to 4.7 kb (Hirsch et al., 2016), and as such, effective use of AAVs involves finding an optimal compromise between size restriction and cellular specificity. This requires a tradeoff between (1) the requirement for the essential elements needed for AAV expression (i.e., the backbone [Powell et al., 2015]) and (2) components such as enhancers or recombinase sites that provide for selective cell-type expression. Here, we systematically considered all constituent components used in existing AAV constructs. To do so, we began by surveying the most commonly used CNS-related plasmids available at Addgene, a non-profit organization, which has become the largest and most utilized repository for AAV plasmids. For the 428 constructs requested more than 20 times (Table S1; see STAR Methods), we systematized the annotation of all elements included in the AAV payload (i.e., between the internal terminal repeats [ITRs]) and classified them into 5 categories: promoters/enhancers, transgenes, woodchuck hepatitis virus post-transcriptional regulatory elements (woodchuck hepatitis virus posttranscriptional regulatory elements, WPREs), polyA sequences, and recombinase recognition sites (Table S1). For all plasmids, we assessed frequency of use and size of backbones and constituent elements (i.e., all elements between ITRs minus the transgene; Figures 1A, 1B, and S1A). As the addition of recombinase-inducible elements (e.g., complex recombination-site configurations, stop cassette) can easily result in exceeding the packaging capability, we further considered the size of each backbone in terms of their recombinase dependency (Figures 1C, 1D, and S1B). While many of these constructs are Cre dependent (141/428), a small fraction are Flp dependent (10/428) or combine both Flp and Cre (10/428). This analysis revealed that among the commonly used plasmids, there exists a wide variability in construct size, resulting from the historical inclusion of both suboptimal elements and extraneous sequences that provide no functional utility. Hence, this highlighted the lack of standardized, robust, and flexible AAV backbones from which to fully exploit the widest range of possible approaches. This also revealed notable gaps in the strategies devised to achieve cell-type specificity, in particular an underutilization of Boolean subtractive approaches.

To address these limitations, we designed, assembled, and validated a set of AAV backbones that constitute a generalizable VTK for targeting and manipulating the nervous system. These plasmids vary in their mode of regulation from simple promoter/enhancer-dependent expression to complex combinatorial expression, dependent on both Cre and Flp recombinases (Figure 2; Table S2). To build these vectors, we incorporated a set of structural elements that represent the best compromise between size and efficiency. Specifically, we included a WPRE sequence of 251 bp and a bovine growth hormone (bGH) polyA sequence of 225 bp in each plasmid to increase transgene expression by stabilizing the resulting mRNA, without affecting the titer of the AAV production (Figure S1B; see STAR Methods) (Donello et al., 1998; Kohara et al., 2014; Pfarr et al., 1986). By building these plasmids using direct DNA synthesis (Table S2), we were able to optimize the size of the backbones while further improving their modularity. This allowed us to strategically incorporate restriction-enzyme recognition sites at key locations to facilitate the cloning of constructs as needed (Figure S2). We then used Boolean strategies to create a set of recombinase-dependent backbones for conditional expression: direct expression from the promoter (VTK1), Cre-recombinase-dependent expression (VTK2, Cre-ON), Flp-recombinase-dependent expression (VTK3, Flp-ON), both Cre- and Flp-recombinase-dependent expression (VTK4, Cre-ON; Flp-ON), Cre-recombinase-dependent expression that is
turned off by Flp recombinase (VTK5, Cre-ON; Flp-OFF), and Flp-recombinase-dependent expression that is turned off by Cre recombinase (VTK6, Cre-OFF; Flp-ON). For improved recombination efficiency, Lox or FRT inducible sites were placed in a double-inverted orientation (DIO) conformation (Atasoy et al., 2008) for ON systems or facing each other for deletion when in an OFF conformation. Each of these iterations is provided in two variants that include either the human synapsin 1 promoter for neuron-specific expression (hSyn for VTKS1–6) (Nieuwenhuis et al., 2021; Kugler et al., 2003) or the human Dlx5/6 enhancer element to further restrict expression to telencephalic GABAergic interneurons (Dlx,VTKD1–6) (Dimidschstein et al., 2016). All constructs, irrespective of the promoter used, optimized AAV payloads. While VTK1–3 backbones are more compact than most of the commonly used plasmids, VTK4–6 constitute backbones that offer ways of targeting specific populations (see yellow and purple dots in Figures 1 and S1). Together, these constructs provide an overarching architecture for inclusion of complex transgenes while retaining flexibility for the myriad of contexts in which they could be useful.

VTK vectors: Transgene expression and cell-type selectivity

To assess the utility of the VTK backbones, we first examined their ability to direct gene expression and then explored their functional effectiveness for visualizing neuronal function or modulating activity. We first tested the expression and specificity of these vectors by inserting various reporters and effector transgenes in VTK1–6 backbones and injecting the corresponding AAVs in mice at various ages and in various brain regions (Table S3). VTKS1-hChR2-tBFP (direct) was injected in the thalamus of wild-type (WT) mice at postnatal day 10 (P10), which led to local expression of tBFP across all neurons in this structure. Consistent with this, labeled projections of these neurons were observed in the expected cortical areas (Figure 3A). VTKS2-HA-GqDREADD-P2A-tBFP (Cre-ON) was injected in the somatosensory cortex (S1) of SST-Cre transgenic animals, which resulted in strong colocalization between the hemagglutinin (HA) tag associated with the viral transgene and somatostatin (SOM) (Figure 3B; 87.32% ± 1.12%, N = 4). VTKS3-TeTLc-P2A-mCherry (Flp-ON) was injected into S1 of SST-FlpO animals, which showed high levels of colocalization of mCherry expression with SOM+ neurons (Figure 3C; 92.26% ± 4.31%, N = 3). VTKD4-APEX2-V5 (Cre-ON; Flp-ON) was injected into S1 of ACTB-FlpE::SST-Cre animals (i.e., ubiquitous expression of FlpE- and SST-specific expression of Cre). In conjunction with the hDlx enhancer, we observed that the vast majority of cells expressing the viral reporter were SOM+ (Figure 3D, SOM+: 83.17% ± 5.95%; other GABAergic, with parvalbumin [PV]: 8.97% ± 2.67%; vasoactive intestinal peptide [VIP]: 5.5% ± 1.22; N = 3). VTKS5-Rabies-Helper (Cre-ON; Flp-OFF) was injected in Lhx6-iCre::Sst-FlpO, which led to a strong transgene expression de-targeted from SOM interneurons (Pouchelon et al., 2021) (Figure 3E; SOM-: 97.42% ± 0.19%, N = 3). VTKD6-APEX2-V5 (Cre-OFF; Flp-ON) was injected into the hippocampus (Figure 3F, SOM-: 97.42% ± 0.19%, N = 3). This resulted in effective targeting of GABAergic interneurons with hDlx (PV+: 78.27% ± 10.99%; VIP+: 11.13% ± 2.55%; N = 3) and the expected exclusion of SOM+ cells due to the Cre deletion (SOM-: 95.5% ± 2.5%). Using these strategies as exemplars, we demonstrate the targeting specificity of all constructs and highlight that the VTK4–6 vectors can be used for effective Boolean logic strategies compatible with the use of large transgenes.

Having demonstrated that these constructs worked independently, we wondered whether AAVs with different enhancers...
Figure 3. Validation of VTK vector cell-type specificity

(A) Example of VTKS1-hChR2-tBFP injection in the thalamus and corresponding thalamocortical projections in the cortex. Scale bar: 100 µm (left) and 200 µm (right).

(B) Colocalization of somatostatin (SOM) and Gq-HA tag showing SST-Cre-specific VTKS2-Dreadd-Gq recombination (87.32% ± 1.12%, N = 4). Scale bar: 100 µm.

(C) Colocalization of SOM with mCherry showing the recombination of VTKS3-TeTLC upon SST-FlpO (92.26% ± 4.31%, N = 3). Scale bar: 100 µm.

(D) Left, colocalization of V5 labeling with SOM and parvalbumin (PV). Scale bar: 100 µm. Right, quantification of V5 colocalization with SOM, PV, and vasoactive intestinal peptide (VIP)-expressing interneurons (SOM: 83.17% ± 5.95%; PV: 8.97% ± 2.67%; VIP: 5.5% ± 1.22%, N = 3) showing the recombination of VTKD4- NES-APEX2 in GABAergic interneurons and primarily in SOM+ cells.

(legend continued on next page)
could be used in combination. In testing this, we noticed that the coinjection of multiple AAVs under the control of different enhancers in the same animal can lead to a complete loss of their original specificity. For example, upon coinjecting two AAVs into the cortex—ndNdx-EGFP, which only targets inhibitory interneurons (Dimidschstein et al., 2016) and CamKII-ttdTomato, which only targets excitatory neurons—we observed an unexpected colocalization of their reporters (Figure S3C). This pattern of interference occurred in most instances where promoters/enhancers with largely distinct expression profiles were used in tandem (data not shown). Therefore, despite the appeal of using different gene-regulatory elements in combination, such experiments should be undertaken with considerable caution.

**VTK vectors: Transgene functionality**

Over the past decade, neurobiologists have developed a diverse armamentarium of genetic tools to examine neuronal ultrastructure, visualization and manipulation of their activity, and connectivity, as well as gene editing. The size of these components varies considerably, and all require different levels of transgene expression. If one wishes to use these tools in the context of complex targeting strategies, this cannot be achieved without integrating them into compact vectors. We thus validated that the VTK backbones can be effectively employed to drive functional expression of genetically encoded tools spanning a wide range of applications: electron microscopy, calcium imaging, optogenetics, chemogenetics, gene editing, and monosynaptic tracing.

**Electron microscopy**

A nuclear-restricted form of APEX2 (Lam et al., 2015) (NLS-APEX2-V5) was inserted into the VTKS3 backbone and injected into the somatosensory cortex of SST-FpO transgenic animals. Nuclear APEX labeling allowed for the structural analysis of SST interneurons using electron microscopy (Figure 4A).

**Calcium imaging**

The calcium sensor GCaMP6f (Chen et al., 2013) integrated in the VTKS1 backbone was used to query changes in neuronal activity in the postnatal visual cortex of a mouse with altered retinal activity (Figure 4B) (Burbridge et al., 2014).

**Optogenetics**

The light-activated opsin ChR2-mCherry (Boyden et al., 2005) was integrated in VTKD2 and injected into the hippocampus of ACTB-Cre mice to test if ChR2-mCherry expression could be restricted to interneurons despite ubiquitous Cre expression. Blue-light stimulation produced depolarization of GABAergic interneurons (Figures 4C, top, and S4A) and resulted in inhibitory synaptic currents in adjacent pyramidal populations. Postsynaptic currents in pyramidal neurons showed a reverse potential of −60 mV and were completely blocked by GABA receptor antagonists (Figures 4C, bottom, and S4B).

**Chemogenetics**

The activating GqDREADD-tBFP (Alexander et al., 2009; Armbruster et al., 2007) was incorporated into VTKS2 and injected into the somatosensory cortex of SST-Cre animals. Three hours following N-oxide (CNO) administration, we observed a strong and specific upregulation of the immediate-early gene cFos in cells expressing the viral reporter (Figure 4D; control [Ctrl]: 4.47% ± 2.4%, N = 3; after CNO: 58.21% ± 5.19%, N = 6).

**Monosynaptic rabies tracing**

The rabies helper transgenes required for monosynaptic retrograde labeling include the coding sequence of a reporter, the cellular receptor for subgroup A avian leukosis viruses (TVA), and rabies glycoprotein, amounting to a 3 kb construct. These transgenes were integrated into VTKS5 and injected into the somatosensory cortex of Lhx6-iCre::SSTFlpO mice (Pouchelon et al., 2021). Following injection of rabies viruses, we observed monosynaptic retrograde labeling from the AAV-targeted cells in the expected thalamic nucleus (Figure 4E).

**Gene editing**

Nkx2.1 CRISPR guide RNA (single guide RNA [sgRNA]) (Sanjana et al., 2014) was inserted upstream of the promoter, which allowed for the insertion of multiple promoter-sgRNA-polyA (3xU6-sgRNA-pA), permitting the incorporation of the NLS-dTomo reporter into a VTKD2 backbone. This was injected in the cholinergic basal forebrain (Magno et al., 2011) of ChAT-Cre::Floxed:stop:Cas9 mice. In cells coexpressing Cas9 with sgRNA and dTomato, Nkx2.1 expression was absent (Figure 4F).

To expand the utility of the set of backbones presented in this study, we produced additional plasmids containing dTomato, GFP, ChR2, or GCaMP6f in either VTKD4–6 or VTKS4–6 backbones. Altogether, this represents a collection of 12 ready-to-use backbones (see Table S2) and 41 effector-containing plasmids (see Table S3) available for AAV production for the neuroscience community via Addgene.

**DISCUSSION**

By surveying the breadth of existing genetic elements utilized in AAV production and selecting streamlined components, we have assembled an optimized set of backbones that can be employed in both direct and combinatorial strategies. This set of tools provides the means for targeting and examining the biological functions of virtually any desired neural population. While our initial aim was to simplify and provide more consistency in AAV-based neuron targeting with the use of VTK, our toolkit also allows for adapting to complex strategies, including the use of the largest effectors commonly employed in neuroscience (i.e., rabies helper transgenes and single-vector multiple CRISPR-gRNA with reporter). While interference at present precludes effective coinjection of multiple AAVs, we expect that further innovation will ultimately overcome this limitation and greatly increase the ability to target different neuronal populations in tandem. We view VTK not as a static toolset but as a platform upon which further innovation will allow for greater flexibility in querying and manipulating neural circuits. We expect this will include both...
Figure 4. Validation of VTK vectors functionality

(A) VTKS3-NLS-APEx2-V5 injected into the somatosensory cortex of SST-FlpO mice allowed for the labeling of sparse populations of nuclei. SST cells with an APEx2-positive nucleus are labeled in yellow (full arrow) and negative ones in blue (empty arrow). Scale bar: 10 μm (left) and 1 μm (right).

(B) Calcium events from VTKS1-GCaMP6f-infected cells were found in the visual cortex of Pax6 knockout (KO) mice. Waves of spontaneous infected cell activity were detected. Graph represents the difference in fluorescence (ΔF/F%) detected in the region of interest (ROI) over time.

(C) Top, cells infected by VTKD2-hChR2-mCherry in dorsal hippocampus of ACTB-Cre mice show depolarization upon blue-light stimulation; bottom, ChR2-mCherry-negative neighboring pyramidal cells receive light-evoked inhibitory postsynaptic currents (IPSCs). IPSCs are blocked by bicuculline (Bic)/picrotoxin (Picro) and CGP55845 (CGP) and GABAa and GABAb receptor antagonists, respectively.

(D) VTKS2-driven DREADd-Gq (tBFP) triggers the expression of the immediate-early gene, cFos, after 3 h of CNO activation compared with the control on the contralateral side (Ctrl: 4.47% ± 2.4%, N = 3; after CNO: 58.21% ± 5.19%, N = 6; data are shown as mean ± SEM). Full arrows: cFos + tBFP colocalization upon activation. Empty arrows: absence of cFos in Ctrl. Scale bar: 50 μm.

(E) Left, VTKS5-rabies helpers (N2cG-eGFP-TVA) are injected in the somatosensory cortex of Lhx6-iCre::SST-FlpO animals. Right, example retrograde labeling tracing found at the thalamus level after secondary rabies infection of helper+ cells. Scale bar: 200 μm (left and right).
in vitro and in vivo applications, notably including free animal behavior. Moreover, while this approach has been optimized for use in rodents, we envision that it will ultimately prove to be efficacious across vertebrate models including primates.

Limitations of the study

Leaky expression

While VTK simplifies the use of AAVs for complex genetics and effector expression, their efficiency and specificity are dependent upon the experimental context. For instance, while driver lines are extremely efficient for targeted deletion or expression of a transgene, mouse lines driving recombinase are not equally effective; this is especially true when recombinases are under an activity-dependent promotor. For instance, VTKS5 did not provide selective deletion from NPY-FlpO animals (data not shown).

Experimental parameters

Additional considerations for experimental design are the use of specific serotypes (Bedbrook et al., 2018), the mode of administration (i.e., intraperitoneal, systemic) (Challis et al., 2019), titer, mode of production (i.e., HEK293 triple-transfection versus Baculovirus [Carinhas et al., 2009; Nasimuzzaman et al., 2018]) and species (i.e., rodents, primates), all of which can considerably influence the level of infection and specificity. In this study, we used AAV serotype 1 for local injection to assess the functionality of the VTK backbone in mice. As such, we recommend that users validate the specificity and functionality of the VTK vectors using the specific parameters imposed by their experimental design. These various parameters have been extensively tested, and the corresponding studies constitute a valuable resource to guide the experimental design (Dimidschstein et al., 2016; Haery et al., 2019; Royo et al., 2008).

AAV quality

Moreover, an essential consideration is the quality of the AAV production; non-specific expression commonly results from the production of AAV particles containing transgenes where recombination occurred during production (Dimidschstein et al., 2016; Haery et al., 2019; Royo et al., 2008). This is typically caused by the presence of latent recombinase activity during the production of AAVs, which especially affects smaller transgenes. To avoid such contamination, the bacterial growth of AAV plasmids for viral production must be tightly controlled (see STAR Methods for details).

Recombinases as transgenes

Due to their high catalytic activity, incorporating recombinases into AAVs can be problematic. This is particularly complicated when the expression of Cre recombinase is placed under the control of enhancer elements (e.g., the mDlx or E2 enhancers; Dimidschstein et al., 2016; Vormstein-Schneider et al., 2020), which can lead to a complete loss of selective targeting. While, in principle, using attenuated versions of Cre recombinase (i.e., Cre, iCre, dCre) or different modes of injection (i.e., systemic, local) might improve the observed specificity, our efforts to do so proved unsuccessful (data not shown). Nonetheless, several groups have, in particular contexts, achieved specificity of expression in select circumstances. For example, the Feng laboratory used the hDlx-Cre construct in Shank3-floxed animals and found that 80% of cells knocked down for Shank3 were interneurons (Fischer et al., 2019). Together, these data suggest that the high level of catalytic activity of these proteins can trigger non-specific recombination even at low levels of expression. This effect can, in principle, be mitigated by using less-active recombinases or in contexts where recombinase-dependent sites are less accessible (e.g., the chromatin of the R26 locus of RCE and Sun1-GFP mouse lines is likely more accessible than the Shank3 locus). As such, the effective use of recombinases in AAVs requires their use to be validated on a case-by-case basis.

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Mice
- **METHOD DETAILS**
  - Addgene plasmids selection and analysis
  - Stereotactic and systemic AAV injections and Rabies injection
  - VTK constructs cloning
  - Recombination sensitive cloning and viruses production
  - Histology
  - Slice electrophysiology
  - Electron microscopy
  - Wide-field calcium imaging
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.crrm.2022.100225.

ACKNOWLEDGMENTS

We thank S. Gerard, P. Delvenne, C. Parotte, D. Joseph, O. Lis, P. Copine, Ma. Matou, P. Noir, Mi. Mi, and Co. Co. for their useful comments on the manuscript. We also thank Kimberly Ritola for sharing EnvA-N2c-dG rabies and her advice on recombination-free AAV production and Bernardo Rudy, Robert Machold, and Benjamin Schuman for discussing their VTKS5 experiment using NPY-FlpO animals. J.D. is supported by NIH grants R01-MH111529 and UG3MH120096 in addition to support from Simons Foundation Award 666155. G.F. was supported by an EMBO Long-Term fellowship, early and advanced Swiss Foundation postdoctoral fellowships, and a Hearst foundation grant, and G.F. was supported by grants from the NIH (MH071679, 566615. G.P. was supported by an EMBO Long-Term fellowship, early and advanced Swiss Foundation postdoctoral fellowships, and a Hearst foundation grant, and G.F. was supported by grants from the NIH (MH071679, 566615).

(F) Three CRISPR guides (sgRNA) targeting Nkx2.1 gene are inserted in VTKD2-NLSdTomato and injected in ChAT-Cre mice::Floxed-Cas9 mice. sgRNA (red) in Cas9-positive (green) cells suppressed Nkx2.1 expression (blue, empty arrows). Cells without colocalization still express Nkx2.1 (full arrows). Scale bar: 50 μm. See also Figure S4 and Table S2.
opment requires patterned activity mediated by retinal acetylcholine receptors. Neuron 84, 1049–1064. https://doi.org/10.1016/j.neuron.2014.10.051.

Carinhas, N., Bernal, V., Yokomizo, A.Y., Carrondo, M.J.T., Oliveira, R., and Alves, P.M. (2009). Baculovirus production for gene therapy: the role of cell density, multiplicity of infection and medium exchange. Appl. Microbiol. Biotechnol. 87, 1041–1049. https://doi.org/10.1007/s00253-008-1727-4.

Challis, R.C., Ravindra Kumar, S., Chan, K.Y., Challis, C., Beadle, K., Jang, M.J., Kim, H.M., Rajendran, P.S., Tompkins, J.D., Shivkumar, K., et al. (2019). Systemic AAV vectors for widespread and targeted gene delivery in rodents. Nat. Protoc. 14, 379–414. https://doi.org/10.1038/s41596-018-0097-3.

Chen, Q., Deister, C.A., Gao, X., Guo, B., Lynn-Jones, T., Chen, N., Wells, M.F., Liu, R., Goard, M.J., Dimidchstein, J., et al. (2020). Dysfunction of cortical GABAAergic neurons leads to sensory hyper-reactivity in a Shank3 mouse model of ASD. Nat. Neurosci. 23, 520–532. https://doi.org/10.1038/s41593-020-0598-6.

Chen, T.-W., Wardill, T.J., Sun, Y., Pulver, S.R., Renninger, S.L., Baohan, A., Schreiter, E.R., Kerr, R.A., Orger, M.B., Jayaraman, V., et al. (2013). Ultrasonic-sensitive fluorescent proteins for imaging neuronal activity. Nature 499, 295–300. https://doi.org/10.1038/nature12354.

Deverman, B.E., Ravina, B.M., Bankiewicz, K.S., Paul, S.M., and Sah, D.W.Y. (2018). Gene therapy for neurological disorders: progress and prospects. Nat. Rev. Drug Discov. 17, 641–659. https://doi.org/10.1038/nrd.2018.110.

Dimidchstein, J., Chen, Q., Tremblay, R., Rogers, S.L., Saldi, G.-A., Guo, L., Xu, Q., Liu, R., Lu, C., Chu, J., et al. (2016). A viral strategy for targeting and manipulating interneurons across vertebrate species. Nat. Neurosci. 19, 1743–1749. https://doi.org/10.1038/nn.4430.

Donello, J.E., Loeb, J.E., and Hope, T.J. (1998). Woodchuck Hepatitis virus contains a tripartite posttranscriptional regulatory element. J. Virol. 72, 5085–5092. https://doi.org/10.1128/JVI.72.5.5085-5092.1998.

Fenno, L.E., Mattis, J., Ramakrishnan, C., Hyun, M., Lee, S.Y., He, M., Tucciarone, J., Selimbeyoglu, A., Berndt, A., Grosenick, L., et al. (2014). Targeting cells with single vectors using multiple-feature Boolean logic. Nat. Meth 11, 763–772. https://doi.org/10.1038/nmeth.2996.

Fenno, L.E., Ramakrishnan, C., Kim, Y.S., Evans, K.E., Lo, M., Vesuna, S., Inoue, M., Cheung, K.Y.M., Yuan, E., Pichamorthy, N., et al. (2020). Comprehensive dual- and triple-feature intersectional single-vector delivery of diverse functional payloads to cells of behaving mammals. Neuron 107, 836–853.e11. https://doi.org/10.1016/j.neuron.2020.06.003.

Fischer, K.B., Collins, H.K., and Callaway, E.M. (2019). Sources of off-target expression from recombinase-dependent AAV vectors and mitigation with cross-over insensitive ATG-out vectors. Proc. Natl. Acad. Sci. 116, 27001–27010. https://doi.org/10.1073/pnas.1915974116.

Fishell, G., and Kepecs, A. (2020). Interneuron types as attractors and controllers. Annu. Rev. Neurosci. 43, 1–30. https://doi.org/10.1146/annurev-neuro-070918-050421.

Graybuck, L.T., Daigle, T.L., Sedero-Cortés, A.E., Walker, M., Kalmbach, B., Lenz, G.H., Morin, E., Nguyen, T.N., Garren, E., Bendrick, J.L., et al. (2021). Enhancer viruses for combinatorial cell-subclass-specific labeling. Neuron 109, 1449–1464.e13. https://doi.org/10.1016/j.neuron.2021.03.011.

Haery, L., Deverman, B.E., Matho, K.S., CETIN, A., Woodard, K., Cepko, C., Guerin, K., Reig, M.A., Ersing, I., Bachle, S.M., et al. (2019). Adeno-associated virus technologies and methods for targeted neuronal manipulation. Front. Neuroanat. 13, 93. https://doi.org/10.3389/fnana.2019.00093.

He, M., Tucciarone, J., Lee, S., Nigro, M.J., Kim, Y., Levine, J.M., Kelly, S.M., Krugkoven, I., Wu, P., Chen, Y., et al. (2016). Strategies and tools for combinatorial targeting of GABAergic neurons in mouse cerebral cortex. Neuron 91, 1229–1243. https://doi.org/10.1016/j.neuron.2016.08.021.

Hirsch, M.L., Wolf, S.J., and Samulski, R.J. (2016). Delivering transgenic DNA exceeding the carrying capacity of AAV vectors. Methods Mol. Biol. 1362, 21–39. https://doi.org/10.1007/978-1-4939-3271-9_2.

Hrvatin, S., Tzenig, C.P., Nagy, M.A., Stroud, H., Koutsoloumpa, C., Wilcox, O.F., Assad, E.G., Green, J., Harvey, C.D., Griffith, E.C., et al. (2019). A
scalable platform for the development of cell-type-specific viral drivers. Elife 8, e48089. https://doi.org/10.7554/eLife.48089.

Hua, Y., Lasereit, P., and Helmsaatder, M. (2015). Large-volume en-bloc staining for electron microscopy-based connectomics. Nat. Commun. 6, 7923. https://doi.org/10.1038/ncomms923.

Jüttner, J., Szabo, A., Gross-Scherf, B., Morikawa, R.K., Rompani, S.B., Hantz, P., Szirka, T., Espositi, F., Cowan, D.S., Bhardwaj, A., et al. (2019). Targeting neuronal and glial cell types with synthetic promoter AAVs in mice, non-human primates and humans. Nat. Neurosci. 22, 1345–1356. https://doi.org/10.1038/s41593-019-0431-2.

Kasthuri, N., Hayworth, K.J., Berger, D.R., Schalek, R.L., Conchello, J.A., Knowles-Barley, S., Lee, D., Vázquez-Reina, A., Kaynig, V., Jones, T.R., et al. (2015). Saturated Reconstruction of a Volume of Neocortex. Cell 162, 648–661. https://doi.org/10.1016/j.cell.2015.06.054.

Kohara, K., Pignatelii, M., Rivest, A.J., Jung, H.-Y., Kitamura, T., Suh, J., Frank, D., Kajikawa, K., Mise, N., Obata, Y., et al. (2014). Cell type-specific genetic and optogenetic tools reveal hippocampal CA2 circuits. Nat. Neurosci. 17, 269–279. https://doi.org/10.1038/nn.3614.

Kügler, S., Klicic, E., and Bähr, M. (2003). Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area. Gene Ther. 10, 337–347. https://doi.org/10.1038/sj.gt.3303105.

Lam, S.S., Martell, J.D., Kamer, K.J., Deerinck, T.J., Ellisman, M.H., Mootha, V.K., and Ting, A.Y. (2015). Directed evolution of APEX2 for electron microscopy and high specificity and performance. Neuron 85, 942–958. https://doi.org/10.1016/j.neuron.2015.02.022.

Mich, J.K., Graybuck, L.T., Hess, E.E., Mahoney, J.T., Kojima, Y., Ding, Y., Somasundaram, S., Miller, J.A., Kalmbach, B.E., Radaelli, C., et al. (2021). Functional enhancer elements drive subclass-selective expression from mouse to primate neocortex. Cell Rep. 34, 108754. https://doi.org/10.1016/j.celrep.2021.108754.

Nasimuzzaman, M., van der Lee, J.C., and Malik, P. (2018). Production and purification of Baculovirus for gene therapy application. J. Vi. Exp., 57019. https://doi.org/10.7594/ed048089.e48089.

Nieuwenhuis, B., Haenzi, B., Hilton, S., Carnicer-Lombarte, A., Hobo, B., Verhaegen, J., and Fawcett, J.W. (2021). Optimization of adeno-associated viral vector-mediated transduction of the corticospinal tract: comparison of four promoters. Gene Ther. 28, 56–74. https://doi.org/10.1038/s41434-020-0169-1.

Pfarr, D.S., Rieser, L.A., Woychik, R.P., Rottman, F.M., Rosenberg, M., and Reff, M.E. (1986). Differential effects of polyadenylation regions on gene expression in mammalian cells. DNA 5, 115–122. https://doi.org/10.1089/dna.1986.5.115.

Pouchelon, G., Dwivedi, D., Bollmann, Y., Agba, C.K., Xu, Q., Mirow, A.M.C., Kim, S., Siu, Y., Sevier, E., Ritola, K.D., et al. (2021). The organization and development of cortical interneuron presynaptic circuits are area specific. Cell Rep. 37, 109993. https://doi.org/10.1016/j.celrep.2021.109993.

Powell, S.K., Rivera-Soto, R., and Gray, S.J. (2015). Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy. Discov. Med. 19, 49–57.

Royo, N.C., Vandenberghe, L.H., Ma, J.-Y., Hauspurg, A., Yu, L., Maronksi, M., Johnston, J., Dichter, M.A., Wilson, J.M., and Watson, D.J. (2008). Specific AAV serotypes stably transduce primary hippocampal and cortical cultures with high efficiency and low toxicity. Brain Res. 1190, 15–22. https://doi.org/10.1016/j.brainres.2007.11.015.

Sanjana, N.E., Shalem, O., and Zhang, F. (2014). Improved vectors and genome-wide libraries for CRISPR screening. Nat. Meth 11, 783–784. https://doi.org/10.1038/nmeth.3047.

Taniuchi, H., He, M., Wu, P., Kim, S., Paik, R., Sugino, K., Kvitvicius, D., Kvitiansi, D., Fu, Y., Lin, Y., et al. (2011). A resource of Cre driver lines for genetic targeting of GABAergic neurons in cerebral cortex. Neuron 71, 995–1013. https://doi.org/10.1016/j.neuron.2011.07.026.

Tasic, B., Yao, Z., Graybuck, L.T., Smith, K.A., Nguyen, T.-N., Bertagnolli, D., Rady, J., Garren, E., Economo, M.N., Viswanathan, S., et al. (2018). Shared and distinct transcriptomic cell types across neocortical areas. Nature 563, 72–78. https://doi.org/10.1038/s41586-018-0654-5.

Vormstein-Schneider, D., Lin, J.D., Pekey, K.A., Chittajallu, R., Guo, B., Arias-Garcia, M.A., Allaway, K., Sakopoulos, S., Schneider, G., Stevenson, O., et al. (2020). Viral manipulation of functionally distinct interneurons in mice, non-human primates and humans. Nat. Neurosci. 23, 1629–1636. https://doi.org/10.1038/s41593-020-0692-9.
# STAR★METHODS

## KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| rabbit anti-somatostatin | Peninsula Laboratories International | T-4103.0050, RRID:AB_518614 |
| guinea pig anti-cFos | Synaptic Systems | #226004, RRID:AB_2619946 |
| anti-tagFP           | Synaptic Systems | FluoTag-X2 N0502-A542, RRID:AB_2744624 |
| anti-tagFP           | Synaptic Systems | FluoTag-X2 At647 RRID:AB_2744626 |
| rat anti-HA          | Sigma   | #1187423001, RRID:AB_390918 |
| chicken anti-GFP     | Aves Labs | #1020, RRID:AB_10000240 |
| rat anti-RFP         | Chromotek | #58, RRID:AB_2338064 |
| mouse anti-V5        | Thermofisher | #R960-25, RRID:AB_2556564 |
| guinea-pig anti-PV   | Swant   | GP-72, RRID:AB_2665495 |
| rabbit anti-SST      | Millipore | MAB354, RRID:AB_2253656 |
| rabbit anti-Nkx2.1   | Abcam   | #ab76013, RRID:AB_1310784 |
| rabbit anti-VIP      |      | N/A |
| Alexa Fluor 405-, 488-, 546-, 594-, or 647-conjugated secondary antibodies | Thermo Fisher Science or Jackson ImmunoResearch | N/A |
| **Bacterial and virus strains** |        |            |
| Tables S2 and S3     | Addgene and this paper | N/A |
| **Deposited data**   |        |            |
| Tables S2 and S3     | In this paper as indicated in the tables | N/A |
| **Experimental models: Organisms/strains** |        |            |
| C57Bl/6              | Jackson Laboratories | RRID:IMSR_JAX:000664 |
| SST-Cre              | Jackson Laboratories | RRID:IMSR_JAX:013044 |
| SST-FlpO             | Jackson Laboratories | RRID:IMSR_JAX:031629 |
| Lhx6-iCre            | Jackson Laboratories | RRID:IMSR_JAX:026555 |
| ACTB-FlpE            | Jackson Laboratories | RRID:IMSR_JAX:005703 |
| ACTB-Cre             | Jackson Laboratories | RRID:IMSR_JAX:003376 |
| ChAT-Cre             | Jackson Laboratories | RRID:IMSR_JAX:031661 |
| Sun1-GFP             | Jackson Laboratories | RRID:IMSR_JAX:020139 |
| RCE                  | Jackson Laboratories | RRID:IMSR_JAX:32037 |
| Cas9eGFP             | Jackson Laboratories | RRID:IMSR_JAX:026179 |
| Pax6a-Cre            | (Marquardt et al., 2001) | N/A |
| a2-nAChRs floxed     | (Burbridge et al., 2014) | N/A |
| **Recombinant DNA**  |        |            |
| Tables S2, S3 and S4 | Addgene and In this paper as indicated in the table | N/A |
| **Software and algorithms** |        |            |
| EMBASSS needle 6.5.0 | (Madeira et al., 2019) | N/A |
| SnapGene Server version 1.1.58 | http://www.snapgene.com | RRID:SCR_015052 |

(Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Gabrielle Pouchelon (pouchel@cshl.edu) and Jordane Dimidschstein (jordane.dimidschstein@gmail.com).

Materials availability
Plasmids generated in this study have been deposited to Addgene and are listed in Tables S2 and S3.

Data and code availability
- All data reported in this paper will be shared by the lead contact upon request.
- All original code is available in this paper’s supplemental information.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Mice
All experiments were approved by and in accordance with Harvard Medical School IACUC protocol number IS00001269, Broad Institute IACUC protocol number 0156-03-17-1 and the National Institutes of Health. C57Bl/6 mice were used for breeding with transgenic mice. Transgenic mice, SST-Cre (stock number: 013044), SST-FlpO (stock number: 031629), Lhx6-iCre (stock number: 026555), ACTB-FlpE (stock number: 005703), ACTB-Cre (stock number: 003376), ChAT-Cre (stock number: 031661), Sun1-GFP (stock number: 021039), RCE (stock number: 32037), Cas9-eGFP (stock number: 026179) are available at Jackson Laboratories. Both female and male animals were used for all experiments. PAX cKO mice were created by crossing Pax6-Cre (Marquardt et al., 2001) to β2-nAChRs floxed mice (Burbridge et al., 2014). Both males and females were included in all experiments.

METHOD DETAILS

Addgene plasmids selection and analysis
A list of commonly used neuroscience-related AAV plasmids was generated from Addgene’s internal database. We defined “commonly used” as having been distributed more than 20 times since the plasmid was made available on Addgene’s website. The list was further refined by manually removing plasmids containing promoters specific to tissues other than the brain, such as the liver-specific TBG promoter. Plasmid features were identified using SnapGene Server version 1.1.58 with the common features that were available by April 2021. For each Addgene plasmid sequence, a list of plasmid features was obtained from SnapGene that included the feature name, type, direction, and location within the sequence (start and end nucleotide). The size of each feature was calculated based on the feature location information. The nucleotide sequence for each feature was extracted from the full plasmid sequence using the feature location information. The nucleotide sequence for each feature was extracted from the full plasmid sequence using the start and end nucleotides (see Table S1). For each of the 445 most-used plasmids obtained from Addgene we used SnapGene’s 1.1.58 annotation to identify the promoter, WPRE, polyA, and inducible elements. Since not every feature was recognized by SnapGene, we improved the annotation in between bacterial origins of replication (oris): (1) 17 plasmids were removed since they did not contain both an ori and an f1 ori; (2) if no ITR was detected in proximity to each ori or f1 ori, the region 62–191 bp from the ori or 85–214 bp from the f1 ori was classified as an ITR, which is based on the mode of ITR location in other plasmids. Thus, 41 ITR annotations have been added; (3) since SnapGene had only annotated WPREs of size 589 bp, with the exception of one WPRE of length 588 bp (whereas the WPRE in VTK is only 432 bp), the EMBOSS needle tool was used to annotate additional WPREs. The tool identified 18 regions that were not yet annotated as WPRE, and after manual inspection, we added annotations for 11 of these; (4) we carefully examined each type of annotation and reclassified elements when needed. For example, IRES was classified as a
miscellaneous feature instead of a Coding Sequence (CDS), while FRT and Lox features were reclassified as inducible sites; (5) the five largest unannotated regions per plasmid after removing CDS elements were inspected and classified manually; (6) if a Kozak sequence together with a T2A, E2A, F2A or P2A element was in between two CDS elements, the entire region between the two CDS elements was also labeled as CDS. The code that was used to perform these steps has been added to the manuscript (Data S1).

Elements listed below were reported in Figure 1:

**Backbone**
- ITR-delimited payload from which all identified “Transgenes” were subtracted

**Promoters/enhancers/introns**
- As labeled by features in SnapGene 1.1.58
- Largest unlabeled space manually annotated as promoters or introns

**Inducible sites**
- As labeled by SnapGene 1.1.58

**Transgenes**
- As labeled by SnapGene 1.1.58
- Largest unlabeled space manually annotated

**WPRE/PolyA**
- As labeled by SnapGene 1.1.58
- Added CW3SL using EMBOSS needle

**Stereotactic and systemic AAV injections and Rabies injection**

**Mouse local**
Stereotactic injections were performed at postnatal time P0-1 (VTKS2, VTKS3, VTKS5, VTKD2-sgRNA, VTKS1-GCaMP6f) or P10 (VTKS1, VTKS3-APEx2-NLS). P0-1 stereotaxic injections were achieved using a neonate adapter (Harvard apparatus). Mouse pups were anesthetized by hypothermia and stereotactically micro-injected using NanojectIII at 1 nl/second with the rAAVs either in somatosensory cortex at P0-1 (from lambda AP+1.4, ML-1.8, DV-0.2) or in the thalamus at P10 (from lambda AP+1.8, ML-1.3, DV-3.1).

Local injections in two-month-old adult mice (VTKD4, VTKD6, VTKD2-ChR2-mCherry, VTKD2-APEx-V5) were performed by stereotactically-guided injections into the S1 cortex (from bregma AP+1, ML±2.9, DV-0.45/-0.7) with 75 nL of virus and the hippocampal area for VTKD6 (from bregma AP+1, ML±2.9, DV-1.5). VTKD2-ChR2-mCherry was injected in the dorsal hippocampus (from bregma AP+2; ML ±1.5; DV -1.1) with 350-600 nL of virus at 100 nL/min. Mice recovered for 2 weeks before being used for recording or IHC.

**Rabies retrograde tracing**
After VTKS5-helpers injection, EnvA-N2dGcrV-H2B-tdTomato (rabies) was injected after SST-FlpO deletion occurred, 5 days after AAV infection in the somatosensory cortex (from lambda AP+2, ML-2, DV-0.25) (Fischer et al., 2019). After VTKS2-3xsgRNA-helpers injection, EnvA-N2cRV was injected at P30 (from bregma AP-1, ML-3, DV-0.87) and animals were perfused 7 days later.

**VTK constructs cloning**
VTKS/D constructs containing the promoter and inducible sites were synthesized (see Table S2) and cloned using Apal/Ascl into a backbone containing ITRs, WPRE and bGHp polyA (from Addgene #52473, a generous gift from Ian Wickersham) (Kohara et al., 2014). For VTKS1-hChR2-tBFP, we cloned the hChR2 coding sequence from the Addgene plasmid #26976 (a generous gift from Karl Deisseroth) and tBFP from the Addgene plasmid #80086 (a generous gift from Connie Cepko); for VTKS2-hM3Dq-P2A-tBFP, we amplified the hM3Dq-P2A coding sequence from Addgene plasmid #83897 (Chen et al., 2020) and tBFP from the Addgene plasmid #80086; for VTKS3-TeTLC-P2A-mCherry, the coding sequence of TeTLC-P2A-mCherry was a generous gift from Rosa Cosarsi; for VTKD4-V5-APEx2-NES and VTKD6-V5-APEx2-NES, we amplified the V5-APEx2-NES coding sequence from the plasmid Addgene #72480 (a generous gift from Alice Ting); for VTKS5-N2cG-P2A-eGFP-P2A-TVA, we amplified the eGFP-P2A-TVA coding sequence from Addgene plasmid #52473 (a generous gift from Tom Jessell) and we cloned N2cG from pAM-CAGGS-FLEX-H2B-GFP-P2A-N2c(G) (Pouchelon et al., 2021).

**Recombination sensitive cloning and viruses production**

**AAV production**
The enhancers, reporters, and effectors were cloned using the Gibson Cloning Assembly Kit (New England BioLabs, catalog no. NEB-E5510S). After cloning and sequencing, the growth time of the transformed DH10B Competent Cells was kept below 12 hours on plates and 10 hours in flask at 37°C. DNA from several clones was recovered with an endotoxin free midi-kit (Zymo D4202). This allows for consistently obtaining low recombination rates detected by PCR. Primers were designed for amplification of plasmids at the junction of each possible recombined form and compared to recombination-free controls. Only clones with a recombinated/not-recombined ratio of 1.0E+05 or greater were considered for further AAV production. The rAAVs were produced using standard production methods. Polyethyleneimine was used for transfection and OptiPrep gradient (Sigma) was used for viral particle purification. Serotype 1 was used to produce the AAVs for local injections in mice. Serotype PHPeB was used for systemic and local injections in mice. Titer was estimated by quantitative PCR with primers for the WPRE sequence that is common to all constructs. All batches
produced were in the range of 5.0E+11 to 5.0E+13 viral genomes per milliliter (see Table S3). VTKS1-hChR2-BFP (local injection in thalamus, injection to perfusion: P10–P30); VTKS2-hM3Dq-P2A-BFP (injection in primary somatosensory cortex, injection to perfusion: P0–P30, cell type specificity) or P0–P5 (function)); VTKS3-TeTLC-P2A-mCherry (injection in primary somatosensory cortex, injection to perfusion: P1–P15); VTKD4-V5-APEx2-NS (local injection in primary somatosensory cortex, injection to perfusion: P60); VTKS5-N2cG-P2A-eGFP-P2A-TVA (local injection in primary somatosensory cortex, injection to perfusion: P0–P30); VTKD6-V5-APEx2-NS (injection in primary somatosensory cortex and hippocampus, injection to perfusion: P60); VTKS3-NLS-APEx2-V5 (injection in primary somatosensory cortex, injection to perfusion: P10–P30); VTKD2-ChR2-mCherry (injection in dorsal hippocampus, injection to perfusion: adult, 2 weeks); VTKD2-x3 U6sgRNA-A-NLSstdTomato (injection in basal forebrain; injection to perfusion: P0/P1–P7); VTKD2-APEx-V5 (injection in primary somatosensory cortex; injection to perfusion: P60–P70), VTKS1-GCaMP6f (injection in primary visual cortex, injection to perfusion: P1–P7); CamKII-ndTom (rAAV1, titer = 6.5E+12 vg/mL, injection in primary somatosensory cortex, injection to perfusion: P70–P77). 

**Rabies production**

EnvA-pseudotyped CVS-N2c(DeltaG)-H2B-tdTomato (titer = 1.4E+07 IU/mL) was generously produced by Kimberly Ritola.

**Histology**

**Tissue processing**

Mice at P28–P32 and P60 for the adult time point, at P5 and P15 for the developmental time point (N = 3 to 6 for each condition) were transcardially perfused with 4% paraformaldehyde (PFA) and brains were fixed overnight or 2hrs in 4% PFA at 4°C. Brains were sectioned at 40 μm or 50 μm using a Leica VTS1000 vibrosector. Floating sections containing AAV-infected cells or their projections were processed for immunohistochemistry. Brain sections were incubated 1–2hrs at room temperature in a blocking solution containing 3% Normal Donkey serum and 0.3% Triton X-100 in PBS, then incubated overnight or 48hrs at 4°C with primary antibodies: rabbit anti-somatostatin (1:3,000; Peninsula Laboratories International, catalog no. T-4103.0050), guinea pig anti-c-fos (1:300, Synaptic Systems, catalog no. #226004), anti-tagFP (1:500; Synaptic Systems, catalog no. FluorTag-X2 N0502, At542 or At647), rat anti-HA (1:1,000; Sigma, catalog no. #11867423001), chicken anti-GFP (1:1,000; Aves Labs, catalog no. #1020), rat anti-RFP (1:1,000; Chromotek, catalog no. #568), mouse anti-V5 (1:500; ThermoFisher, catalog no. #R960-25), guinea-pig anti-PV (1:2,000; Swant, catalog no. GP-72), rabbit anti-SST (1:500; Millipore, catalog no. MA8354), rabbit anti-Nkx2.1 (1:2000, Abcam, catalog no. ab76013). The rabbit anti-VIP antibody was a gift from the Salk Institute; it was generated by Joan Vaughan at the Saghatelian lab, and validated by Paul Sawchenko and Josselyn Vergara. Sections were rinsed four times in PBS and incubated for 60–90 min at room temperature or overnight at 4°C with the Alexa Fluor 405-, 488-, 546-, 594-, or 647-conjugated secondary antibodies (1:1000; Thermo Fisher Science or Jackson ImmunoResearch).

**Imaging**

Each brain section containing labeled cells was acquired as a tiled image on a motorized Zeiss Axio Imager A1 or a Zeiss confocal LSM800 using the 10x objective. For quantification of co-localization, cells expressing the indicated reporter were counted using Fiji (ImageJ) using only the corresponding color channel and then, among these cells, the number of cells co-expressing the marker of interest was manually counted or using automated quantification (https://github.com/jessdlin/cellcounter). A cell was considered to be positive for a given marker if the corresponding signal was above background fluorescence. The ratio of cells co-expressing both markers over the total number of cells expressing only the reporter was then calculated and reported as mean ± s.e.m. Quantifications were performed using a minimum of two independent biological replicates. Several sections from the same animal were used when indicated. Data collection and analysis were not performed blind to the conditions of the experiments, but experimenters from different research groups performed the quantification.

**Slice electrophysiology**

Mice were anesthetized with isoflurane and then decapitated. The brain was dissected out in ice-cold sucrose substituted artificial cerebrospinal fluid (SSaCSF) containing the following (in mM): 90 sucrose, 80 NaCl, 3.5 KCl, 24 NaHCO3, 1.25 NaH2PO4, 4.5 MgCl2, 0.5 CaCl2, and 10 glucose, saturated with 95% O2 and 5% CO2. Transverse hippocampal slices (300-350 μm, in coronal or horizontal sections respectively) were cut using a VT-1200S vibratome (Leica Microsystems) and incubated submerged in the above solution at 32-34°C for 30–40 min and then maintained at room temperature until use in the SSaCSF. For patch-clamp recordings following recovery slices were transferred to an upright microscope (Zeiss Axioskop), perfused with aCSF consisting of the following (in mM): 130 NaCl, 3.5 KCl, 24 NaHCO3, 1.25 NaH2PO4, 1.5 MgCl2, 2.5 CaCl2, and 10 glucose, saturated with 95% O2 and 5% CO2 at 2-3 mL/min at a temperature of 32°C-34°C C. For pharmacological dissection of GABA transmission aCSF was supplemented as indicated with (in μM): 50 picrotoxin, 10 bicuculline, 2 CGP 55845 all from Tocris (UK). Individual cells were visualized using a 40x objective using fluorescence and IR-DIC video microscopy. Electrodos were pulled from borosilicate glass (World Precision Instruments) to a resistance of 3–5 MΩ using a vertical pipette puller (Narishige, PP-830). Whole-cell patch-clamp recordings were made using a Multiclamp 700A amplifier (Molecular Devices), and signals were digitized at 20 kHz (Digidata 1322A, filtered at 3 kHz) for collection on a PC computer equipped with pClamp 9.2 or 10.4 software (Molecular Devices). Intracellular recording solution was composed of (in mM): 130 K-gluconate, 5 KCl, 10 HEPES, 3 MgCl2, 2 Na2ATP, 0.3 NaGTP, 0.6 EGTA, and 0.2% bicucytin (ECl– ~ −65 mV). Uncompensated series resistance ranged from 10 to 20 MΩ and was monitored continuously throughout recordings with −5 mV voltage steps. For...
current-clamp recordings of RFP+ cells membrane potential was biased between −55 and −60 mV. Optogenetic events were evoked with brief blue light (470 nm, 2.5–5 ms) stimulation from an LED source (CoolLED PE4000, Andover, UK) through the 40x water-immersion objective. After biocytin filling during whole-cell recordings, slices were fixed with 4% paraformaldehyde and stored at 4 °C then permeabilized with 0.3% Triton X-100 and incubated with Alexa Fluor 488-conjugated streptavidin. In addition, fixed sections were processed for mCherry staining with rabbit anti-RFP at 1:1,000 (Antibodies Online, catalog no. ABIN129578) primary and Alexa-555-conjugated secondary at 1:500 (Invitrogen). Resectediong slices were mounted on gelatin-coated slides using Mowiol mounting medium.

Electron microscopy

Brains were prepared in the same manner and as previously described (Hua et al., 2015). Briefly, an anesthetized animal was first transcardially perfused with 10 mL 0.1 M Sodium Cacodylate (cacodylate) buffer, pH 7.4 (Electron microscopy sciences (EMS)) followed by 20 mL of fixative containing 2% paraformaldehyde (EMS), 2.5% glutaraldehyde (EMS) in 0.1 M Sodium Cacodylate (cacodylate) buffer, pH 7.4 (EMS). The brain was removed and placed in fixative for at least 24 hours at 4°C. The brain was then mounted to the vibratome (Leica VT1200) on the anterior side, and carefully sectioned down through the cerebellum until it just touched the posterior cortex. The brain was then completely sectioned into a series of 300 μm vibratome sections, placed in order into a 24 well dish, and incubated into fixative for another 24 hours at 4°C. Apex2 precipitation and polymerization was performed by washing slices extensively in the cacodylate buffer at room temperature, followed by incubation in 50 mg/mL 3,3′diaminobenzidine (DAB) in the cacodylate buffer for 1 hour at room temperature. 0.003% (v/v) H2O2 until a visible precipitate forms (15–20 minutes). Slices were washed extensively in cacodylate buffer then further reduced in 0.8%(w/v) Sodium Hydrosulfite in 60%(v/v) 0.1 M Sodium Bicarbonate 40%(v/v) 0.1 M Sodium Carbonate for 20 minutes, and washed in cacodylate buffer, 3 exchanges, 10 minutes each. A small region (~1 × 1 mm) around the DAB precipitate was excised from the vibratome sections and prepared for EM by staining sequentially with 2% osmium tetroxide (EMS) in cacodylate buffer, 2.5% potassium ferrocyanide (Sigma-Aldrich), thiocarbohydrazide, unbuffered 2% osmium tetroxide, 1% uranyl acetate, and 0.66% Aspartic acid buffered Lead (II) Nitrate with extensive rinses between each step with the exception of potassium ferrocyanide. The sections were then dehydrated in ethanol and propylene oxide and infiltrated with 812 Epon resin (EMS, Mixture: 49% Embed 812, 28% DDSA, 21% NMA, and 2.0% DMP 30). The resin-infiltrated tissue was cured at 60°C for 3 days. Using a commercial ultramicrotome (Powertome, RMC), the cured block was trimmed to a ~1.0mm × .8 mm rectangle and 40nm thick sections were collected from the tissue block on polyamide tape (Kapton) using an automated tape collecting device (ATUM, RMC) and assembled on silicon wafers as previously described (Kasthuri et al., 2015). The sections were imaged using backscattered electron detection with a Gemini 300 scanning electron microscope (Carl Zeiss), equipped with ATLAS software for wafer imaging.

Wide-field calcium imaging

Mice were given analgesic (Meloxicam) one hour before surgery and then anesthetized with isoflurane (3% briefly for induction and surgery, then 0.75%-1% for headbar preparation) before preparing for imaging by removing the skin above primary visual cortex and affixing a clear glue cap which was attached to head bars at the anterior and posterior of the imaging region. Skull thickness is very thin at early postnatal ages (P7, in this study) and calcium sensor signal is bright enough at this age to image directly through a hardened glue cap and the skull into V1. After recovery from anesthesia for at least 30 minutes spontaneous activity was recorded in 0.2s increments for five minute increments using LED stimulation, a 4x objective, and a camera. After two or three movies the animal was again anesthetized and sacrificed. Images were generated with Fiji (https://imagej.nih.gov/ij/) and movies analyzed with MATLAB as previously described (Ackman et al., 2012).

QUANTIFICATION AND STATISTICAL ANALYSIS

For each experiment, animals with fewer than 10 infected cells were removed from the study. For cell specificity quantification, Fiji software (https://imagej.nih.gov/ij/) was used both for manual or automated quantifications. Data collection and analysis were not performed blind to the conditions of the experiments, but experimenters from different research groups performed the quantification. Two to five independent biological replicates (N), animals were used for the analysis. Several sections from the same animal were averaged when indicated. The number of animals (N) was determined based on previously published work (Pouchelon et al., 2021; Vormstein-Schneider et al., 2020). Data are represented as mean ± s.e.m.

Electrophysiological data were acquired on pClamp 9.2 or 10.4 software (Molecular Devices) on one animal from 4 pyramidal cells in different slices. All of them showed the response illustrated in the figure. Electron microscopy was replicated on four animals, with staining detected in all. Two animals were imaged and one illustrated in the figure. Calcium imaging experiment was replicated on 10 animals.